Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript February 28, 2025
Apellis Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.29, expectations were $-0.37.
Meredith Kaya: Good morning, and thank you for joining us to discuss Apellis Pharmaceuticals, Inc.’s fourth quarter and full year 2024 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois, Executive Vice President of Commercial, David...
